Letters
Insulin manufacture
Marketing insulins
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d471 (Published 25 January 2011) Cite this as: BMJ 2011;342:d471
- Robert Tattersall, retired professor of clinical diabetes1
- 1Sheffield S11 7EJ, UK
- robert.tattersall021{at}gmail.com
Cohen and Carter point out the lack of evidence that analogues are better than human insulin and conclude that marketing accounts for their success.1 We have been here before.
In the 1970s, human insulin was thought in some unspecified way to be better than animal insulin, and Novo and Eli Lilly started a race to make and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £138 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£23 / $37 / €30 (inc. VAT)
You can download a PDF version for your personal record.